Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duch
Go back to Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duch| SAREPTA THERAP (NASDAQ: SRPT) | Delayed: 18.20 +0.23 (1.28%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.97 | 52 Week High | $63.73 | |||
| Open | $18.23 | 52 Week Low | $8.00 | |||
| Day High | $18.41 | P/E | N/A | |||
| Day Low | $17.45 | EPS | $-5.69 | |||
| Volume | 3,425,396 | |||||
